Current opinion on optimal treatment for colorectal cancer

摘要: The medical treatment of colorectal cancer (CRC) has evolved greatly in the last 10 years, involving complex combined chemotherapy protocols and, more recent times, new biologic agents. Advances adjuvant therapy have been limited to addition oxaliplatin and substitution oral fluoropyrimidine (e.g., capecitabine) for intravenous 5-fluorouracil with no evidence improved outcome biological Clinical benefit from use targeted monoclonal antibodies, bevacizumab, cetuximab panitumumab, metastatic CRC is now well established, but optimal timing their requires careful consideration derive maximal benefit. Evidence date suggests potentially distinct roles bevacizumab EGF receptor-targeted agents (cetuximab panitumumab) CRC. This article reviews support modern treatments decision-making behind choices, benefits toxicities.